Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M65T | ISIN: SE0002148817 | Ticker-Symbol: 24H
Stuttgart
21.11.24
08:13 Uhr
2,566 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HANSA BIOPHARMA AB Chart 1 Jahr
5-Tage-Chart
HANSA BIOPHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,5482,62815:50

Aktuelle News zur HANSA BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.11.HANSA BIOPHARMA AB: Hansa Biopharma to Attend Jefferies London Healthcare Conference3
30.10.Hansa Biopharma AB: Hansa Biopharma to Attend Truist Securities BioPharma Symposium192LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York...
► Artikel lesen
18.10.Telefonkonferenz zu Quartalszahlen: Hansa Biopharma meldet Rekordumsatz für IDEFIRIX im dritten Quartal 20242
18.10.Earnings call: Hansa Biopharma reports record IDEFIRIX sales in Q3 20242
17.10.Hansa Biopharma Q3 GAAP EPS of -SEK 1.53, revenue of SEK78.4M1
HANSA BIOPHARMA Aktie jetzt für 0€ handeln
17.10.Hansa Biopharma AB: Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results174Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance LUND, Sweden, Oct. 17, 2024 /PRNewswire/ -- Hansa Biopharma...
► Artikel lesen
07.10.Hansa Biopharma AB: Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial190LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from...
► Artikel lesen
03.10.HANSA BIOPHARMA AB: Hansa Biopharma to host Q3 2024 interim results conference call9
05.09.Hansa Biopharma AB: Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference216LUND, Sweden, Sept. 5, 2024 /PRNewswire/ -- Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial...
► Artikel lesen
23.08.Hansa Biopharma AB: Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis815LUND, Sweden, Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US...
► Artikel lesen
22.07.Earnings call: Hansa Biopharma reports solid Q2 with growth in Idefirix sales3
18.07.Hansa Biopharma Q2 GAAP EPS of -SEK3.301
18.07.Hansa Biopharma AB: Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update473LUND, Sweden, July 18, 2024 /PRNewswire/ -- Hansa Biopharma today announced its first half and second quarter 2024 financial results and business update. Søren Tulstrup, President and...
► Artikel lesen
03.07.Hansa Biopharma AB: Hansa Biopharma to host Q2 2024 interim results conference call294LUND, Sweden, July 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may...
► Artikel lesen
28.06.Hansa Biopharma AB: Hansa Biopharma: increase in number of shares and votes702LUND, Sweden, June 28, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa Biopharma" or the "Company") (NASDAQ: HNSA) (STOCKHOLM: HNSA) today announced that Hansa's registered share capital...
► Artikel lesen
27.06.Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)1
07.06.HANSA BIOPHARMA AB: Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm5
31.05.Hansa Biopharma AB: Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial810LUND, Sweden, May 31, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial...
► Artikel lesen
27.05.Notice to Annual General Meeting in Hansa Biopharma AB (publ)4
21.05.Hansa Biopharma AB: Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting260LUND, Sweden, May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant...
► Artikel lesen
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1